Cytokinetics CEO exercises options, sells 7,500 shares

The CEO's reported trades were under a Rule 10b5-1 plan, and 149,245 non-qualified stock options remained after the exercise.

Rhea-AI Filing Summary

Cytokinetics, Inc. President & CEO Robert I. Blum exercised 7,500 non-qualified stock options on September 28, 2026, at $10.60 per share, acquiring 7,500 common shares and selling those shares at $65.46 per share the same day. The transactions were reported under a Rule 10b5-1 plan. After the exercise, Blum held 149,245 non-qualified stock options. Separately, the reported holdings include 2,083 shares each held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust; Blum disclaims beneficial ownership of those trust shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($411K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($491K)

Approx. gross sale proceeds $491K

Approx. exercise cost $80K

Approx. pre-tax spread $411K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$10.60	$80K
Sale	Common Stock	7,500	$65.46	$491K
holding	Common Stock F1	--	--	--
holding	Common Stock F2	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 149,245 contracts (Direct); Common Stock — 278,544 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1. Beneficial Ownership disclaimed.); Common Stock — 2,083 shares (Indirect, by Trust 2. Beneficial Ownership Disclaimed.); Common Stock — 0 shares (Indirect, by Trust 3. Beneficial Ownership Disclaimed.)

Footnotes (2)

1. F1. Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
2. F2. Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

Key Figures

Common shares sold: 7,500 shares Sale price: $65.46 per share Non-qualified stock options exercised: 7,500 options +4 more

7 metrics

Common shares sold 7,500 shares September 28, 2026

Sale price $65.46 per share Common shares sold September 28, 2026

Non-qualified stock options exercised 7,500 options September 28, 2026

Exercise price $10.60 per share Options exercised September 28, 2026

Non-qualified stock options following exercise 149,245 options Reported following the September 28, 2026 exercise

Shares held by The Bridget Blum 2003 Irrevocable Trust 2,083 shares Reported trust holding; Robert I. Blum disclaims beneficial ownership

Shares held by The Brittany Blum 2003 Irrevocable Trust 2,083 shares Reported trust holding; Robert I. Blum disclaims beneficial ownership

Key Terms

Non-Qualified Stock Option (Right to Buy), Beneficial Ownership, co-trustee

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"Non-Qualified Stock Option (Right to Buy)"

Beneficial Ownership financial

"disclaims any beneficial ownership interest in the Shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

co-trustee regulatory

"of which reporting person is a co-trustee"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CYTK shares did the CEO sell?

Robert I. Blum, Cytokinetics' President & CEO, sold 7,500 common shares at $65.46 per share on September 28, 2026. The transactions were reported under a Rule 10b5-1 plan.

How many CYTK stock options did the CEO exercise?

Robert I. Blum exercised 7,500 non-qualified stock options at $10.60 per share on September 28, 2026, acquiring 7,500 common shares. The reported option balance following the exercise was 149,245.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 04:55 PM Accepted by SEC EDGAR 09/28/2026 - 04:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/28/2026		M		7,500	A	$10.6	286,044	D
Common Stock	09/28/2026		S		7,500	D	$65.46	278,544	D
Common Stock								2,083	I	by Trust 1. Beneficial Ownership disclaimed.(1)
Common Stock								2,083	I	by Trust 2. Beneficial Ownership Disclaimed.(2)
Common Stock								0	I	by Trust 3. Beneficial Ownership Disclaimed.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	09/28/2026		M			7,500	03/28/2017	02/28/2027	Common Stock	7,500	$0	149,245	D

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)